Research Analysts Issue Forecasts for CADL FY2024 Earnings

Candel Therapeutics, Inc. (NASDAQ:CADL) – Stock analysts at HC Wainwright decreased their FY2024 EPS estimates for Candel Therapeutics in a research report issued to clients and investors on Monday, November 18th. HC Wainwright analyst V. Bernardino now anticipates that the company will earn ($1.65) per share for the year, down from their previous forecast of ($0.91). HC Wainwright has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Candel Therapeutics’ current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Candel Therapeutics’ FY2025 earnings at $0.15 EPS.

Candel Therapeutics Stock Performance

NASDAQ CADL opened at $4.14 on Wednesday. The stock has a market capitalization of $134.30 million, a price-to-earnings ratio of -2.39 and a beta of -0.88. The business’s 50 day moving average is $5.86 and its two-hundred day moving average is $6.66. Candel Therapeutics has a 12-month low of $0.77 and a 12-month high of $14.30. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 1.66.

Insider Activity at Candel Therapeutics

In other news, major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of the stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $6.02, for a total value of $90,300.00. Following the completion of the transaction, the insider now owns 929,873 shares in the company, valued at $5,597,835.46. This trade represents a 1.59 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold a total of 31,800 shares of company stock worth $193,380 over the last three months. 41.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Candel Therapeutics

Several hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp acquired a new stake in Candel Therapeutics in the second quarter valued at $338,000. Rhumbline Advisers purchased a new stake in shares of Candel Therapeutics in the 2nd quarter worth about $143,000. Point72 DIFC Ltd acquired a new stake in Candel Therapeutics in the 2nd quarter valued at about $31,000. Cubist Systematic Strategies LLC purchased a new position in Candel Therapeutics during the 2nd quarter valued at about $162,000. Finally, FMR LLC acquired a new position in Candel Therapeutics during the third quarter worth about $46,000. 13.93% of the stock is owned by hedge funds and other institutional investors.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.